The startup manufactures diagnostic tools and pharmaceuticals for clinical oncology, cardiology, neurology, and infectious-inflammatory diseases, focusing on the production and distribution of positron emission tomography (PET) agents and both IP and generic drugs for clinical trials. By providing standardized diagnostic solutions, the company enhances the accuracy and efficiency of pharmacists in delivering patient care.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Positron emission tomography (PET) scans are crucial for diagnosing and monitoring diseases like cancer, but the production and distribution of radiopharmaceutical drugs required for these scans can be complex and require specialized facilities. This complexity can limit the availability and accessibility of these essential diagnostic tools.
Solution
Nucleis Radiopharmaceuticals manufactures and distributes radiopharmaceutical drugs used in nuclear medicine for diagnostic imaging and therapy monitoring. The company focuses on positron emission tomography (PET) tracers, including its own Glucotrace product (fludeoxyglucose (18F)), as well as investigational medicinal products (IMPs) for clinical trials. Nucleis also acts as a contract manufacturing organization (CMO), producing radiopharmaceuticals for other companies, including authorized drugs like Vizamyl and Axumin. By providing both generic and IP radiopharmaceuticals, Nucleis supports the advancement of early disease detection, treatment, and monitoring.
Target Audience
The primary customers are nuclear medicine departments in hospitals and clinics equipped with PET-CT scanners, as well as pharmaceutical companies requiring contract manufacturing of radiopharmaceuticals.
Features
- Manufacturing and distribution of Glucotrace (fludeoxyglucose (18F)) for oncology, cardiology, neurology, and infectious/inflammatory diseases
- Contract manufacturing services for radiopharmaceutical drugs, including both authorized drugs and investigational medicinal products
- GMP-certified manufacturing facilities for human medicinal products and human investigational medicinal products
- Marketing Authorization Holder for Glucotrace in Belgium, the Netherlands, Luxembourg, France, and Germany
- Manufacturing of Axumin TM under authorization from Blue Earth Diagnostics for prostate cancer imaging
- Manufacturing of Vizamyl TM under authorization from GE Healthcare for Alzheimer's disease imaging